Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis1

Clinical and Experimental Immunology

Volumn 181, Issue 1, 2015, Pages 100-109

  Favoino, E ^a   Favia, I E ^a   Vettori, S ^b   Vicenti, C ^a   Prete, M ^a   Valentini, G ^b   Perosa, F ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

HLA G; HLA G genotype; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; GENOMIC DNA; HLA G ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INDEL MUTATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROLOGY; SYSTEMIC SCLEROSIS; BLOOD; GENE FREQUENCY; GENETICS; IMMUNOLOGY; MONONUCLEAR CELL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

FEMALE; GENE FREQUENCY; HLA-G ANTIGENS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 84930417658     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12633     Document Type: Article

References (45)

1. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117:557-67.
2. Guy S, Kong J, Cheema GS, Keen CL, Wick G, Gershwin ME. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008; 38:132-60.
3. Prete M, Fatone MC, Favoino E, Perosa F. Raynaud's phenomenon: from molecular pathogenesis to therapy. Autoimmun Rev 2014; 13:655-67.
4. De Palma R, Del Galdo F, Lupoli S, Altucci P, Abbate G, Valentini G. Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin. Clin Exp Immunol 2006; 144:169-76.
5. van der Ven K, Pfeiffer K, Skrablin S. HLA-G polymorphisms and molecule function-questions and more questions-a review. Placenta 2000; 21 (Suppl. A):S86-92.
6. Kirszenbaum M, Moreau P, Gluckman E, Dausset J, Carosella E. An alternatively spliced form of HLA-G mRNA in human trophoblasts and evidence for the presence of HLA-G transcript in adult lymphocytes. Proc Natl Acad Sci USA 1994; 91:4209-13.
7. Perosa F, Prete M, Luccarelli G, Favoino B, Ferrone S, Dammacco F. Serum levels of beta-2-microglobulin-free heavy chain of HLA class I antigen in healthy individuals: relationship to their class I allotype. Hum Immunol 1999; 60:1058-66.
8. Park GM, Lee S, Park B et al. Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophys Res Commun 2004; 313:606-11.
9. Diaz-Lagares A, Alegre E, LeMaoult J, Carosella ED, Gonzalez A. Nitric oxide produces HLA-G nitration and induces metalloprotease-dependent shedding creating a tolerogenic milieu. Immunology 2009; 126:436-45.
10. Cirulli V, Zalatan J, McMaster M et al. The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G. Diabetes 2006; 55:1214-22.
11. Menier C, Rabreau M, Challier JC, Le DM, Carosella ED, Rouas-Freiss N. Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis. Blood 2004; 104:3153-60.
12. Le Bouteiller P, Solier C, Proll J, guerre-Girr M, Fournel S, Lenfant F. Placental HLA-G protein expression in vivo: where and what for? Hum Reprod Update 1999; 5:223-33.
13. Riteau B, Menier C, Khalil-Daher I et al. HLA-G inhibits the allogeneic proliferative response. J Reprod Immunol 1999; 43:203-11.
14. Le Rond S, Azema C, Krawice-Radanne I et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells. J Immunol 2006; 176:3266-76.
15. Feger U, Tolosa E, Huang YH et al. HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. Blood 2007; 110:568-77.
16. Liang S, Ristich V, Arase H, Dausset J, Carosella ED, Horuzsko A. Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6-STAT3 signaling pathway. Proc Natl Acad Sci USA 2008; 105:8357-62.
17. Creput C, Durrbach A, Menier C et al. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol 2003; 39:587-94.
18. Qiu J, Terasaki PI, Miller J, Mizutani K, Cai J, Carosella ED. Soluble HLA-G expression and renal graft acceptance. Am J Transplant 2006; 6:2152-6.
19. Bukur J, Rebmann V, Grosse-Wilde H et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 2003; 63:4107-11.
20. Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005; 105:1694-8.
21. Brenol CV, Veit TD, Chies JA, Xavier RM. The role of the HLA-G gene and molecule on the clinical expression of rheumatologic diseases. Rev Bras Reumatol 2012; 52:82-91.
22. Verbruggen LA, Rebmann V, Demanet C, De CS, Grosse-Wilde H. Soluble HLA-G in rheumatoid arthritis. Hum Immunol 2006; 67:561-7.
23. Rizzo R, Farina I, Bortolotti D et al. HLA-G may predict the disease course in patients with early rheumatoid arthritis. Hum Immunol 2013; 74:425-32.
24. Rosado S, Perez-Chacon G, Mellor-Pita S et al. Expression of human leukocyte antigen-G in systemic lupus erythematosus. Hum Immunol 2008; 69:9-15.
25. Zhang JB, Wang ZY, Chen J, Wu XD, Zhou B, Yie SM. The expression of human leukocyte antigen G (HLA-G) is associated with sacroiliitis stages of ankylosing spondylitis. Immunol Lett 2013; 152:121-5.
26. Park KS, Park JS, Nam JH, Bang D, Sohn S, Lee ES. HLA-E*0101 and HLA-G*010101 reduce the risk of Behcet's disease. Tissue Antigens 2007; 69:139-44.
27. Kim JJ, Hong SJ, Hong YM et al. Genetic variants in the HLA-G region are associated with Kawasaki disease. Hum Immunol 2008; 69:867-71.
28. Wastowski IJ, Sampaio-Barros PD, Amstalden EM et al. HLA-G expression in the skin of patients with systemic sclerosis. J Rheumatol 2009; 36:1230-4.
29. 29. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-90.
30. Walker UA, Tyndall A, Czirjak L et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group database. Ann Rheum Dis 2007; 66:754-63.
31. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-5.
32. Clements P, Lachenbruch P, Siebold J et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22:1281-5.
33. Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA Jr. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985; 28:759-67.
34. Hsu VM, Moreyra AE, Wilson AC et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008; 35:458-65.
35. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della RA, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003; 21:S42-6.
36. Valentini G, Della RA, Bombardieri S et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001; 60:592-8.
37. Valentini G, Bencivelli W, Bombardieri S et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003; 62:901-3.
38. Valentini G, Medsger TA Jr, Silman AJ, Bombardieri S. Conclusion and identification of the core set of variables to be used in clinical investigations. Clin Exp Rheumatol 2003; 21:S47-8.
39. Boiocchi C, Bozzini S, Zorzetto M, Pelissero G, Cuccia M, Falcone C. Association between two polymorphisms in the HLA-G gene and angiographic coronary artery disease. Mol Med Rep 2012; 5:1141-5.
40. Herzenberg LA, De Rosa SC, Dubs JG et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci USA 1997; 94:1967-72.
41. Prigione I, Penco F, Martini A, Gattorno M, Pistoia V, Morandi F. HLA-G and HLA-E in patients with juvenile idiopathic arthritis. Rheumatology (Oxf) 2011; 50:966-72.
42. Rizzo R, Hviid TV, Govoni M et al. HLA-G genotype and HLA-G expression in systemic lupus erythematosus: HLA-G as a putative susceptibility gene in systemic lupus erythematosus. Tissue Antigens 2008; 71:520-9.
43. Rizzo R, Rubini M, Govoni M et al. HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet Genomics 2006; 16:615-23.
44. Akhter A, Faridi RM, Das V, Pandey A, Naik S, Agrawal S. In vitro up-regulation of HLA-G using dexamethasone and hydrocortisone in first-trimester trophoblast cells of women experiencing recurrent miscarriage. Tissue Antigens 2012; 80:126-35.
45. Valentini G, Marcoccia A, Cuomo G et al. Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and/or capillaroscopic positivity. Arthritis Care Res (Hoboken) 2014; 66:1520-7.